More nonsense from the article: "Multiple myeloma metastatic to the skin is a rare occurrence that usually reflects a high tumour burden."
How in the hell is someone with a rare occurrence of when multiple myeloma metastasizes to the skin is going to become involved in a efficacy study for a topical cream to treat psoriasis?
This arguments is weak at best.
First do you understand how rare multiple Myeloma effects fewer than 200,000 people in the U.S.
So in the US that is 0.06% of the population.
The population of Israel is 8.5 million.
That is 5100 people in Israel that have Multiple Myeloma - so the chances that the efficacy study has the one of the 5100 (and mush less than that with MM that has metastasized to the skin) is so small that it isn't possible to believe the OWCP nonsense for the delay in the efficacy report.
News 
Market Data 
Discover 
